Imatinib
3 Inquiries
152459-95-5
Pharmaceutical Grade
99%
SHANGHAI
25kg/2.5kg Fiber Drum
Yes
2095-06-30
Imatinib mesylate
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
Imatinib is an oral medication used to treat chronic, accelerated and chronic phase of failure of interferon treatment in adults with chronic myelogenous leukemia (CML) in Philadelphia chromosomes (Ber-Abl) . CML is a hematopoietic stem cell disorder caused by abnormal DNA of stem cells in the bone marrow. Abnormal DNA can produce abnormal protein, interfere with the normal process of bone marrow white blood cells, eventually leading to a sharp increase in the number of white blood cells. CML is divided into chronic phase, accelerated phase and crisis phase of three stages, the crisis of patients with an average survival of only 2-3 months between elbows. Imatinib is an oral medication used to treat chronic, accelerated and chronic phase of failure of interferon treatment in adults with chronic myelogenous leukemia (CML) in Philadelphia chromosomes (Ber-Abl) . CML is a hematopoietic stem cell disorder caused by abnormal DNA of stem cells in the bone marrow. Abnormal DNA can produce abnormal protein, interfere with the normal process of bone marrow white blood cells, eventually leading to a sharp increase in the number of white blood cells. CML is divided into chronic phase, accelerated phase and crisis phase of three stages, the crisis of patients with an average survival of only 2-3 months between elbows.
English name: Imatinib
CAS No : 152459-95-5
Molecular formula: C29H31N7O
Molecular weight: 493.6
ECHEMI Editorial ReferenceOrange SolidImatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal prote
Solid
Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It derives from a benzamide.|Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.|Imatinib is a Kinase Inhibitor. The mechanism of action of imatinib is as a Protein Kinase Inhibitor.|Imatinib is specific tyrosine kinase receptor inhibitor that is used in the therapy of Philadelphia chromosome-positive chronic myelogenous leukemia and gastrointestinal stromal tumors, both of which are marked by an abnormal, constitutively expressed tyrosine kinase that causes unregulated cell growth. Imatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury which can be severe and sometimes fatal.|Imatinib is an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST). This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins.|A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.Basic Info-
Product Name:
Imatinib
Other Name:Benzamide,4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-;4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide;CGP 57148;Imatinib;4-(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide;Genfatinib;N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
CAS No.:152459-95-5
Molecular Formula:C29H31N7O
InChIKeys:InChIKey=KTUFNOKKBVMGRW-UHFFFAOYSA-N
Molecular Weight:493.6
Exact Mass:493.60
EC Number:1308068-626-2
UNII:BKJ8M8G5HI
NSC Number:759854|743414
DSSTox ID:DTXSID3037125
NCI Thesaurus Code:C62035
ATC Code:L01XE01|L - Antineoplastic and immunomodulating agents
HScode:29339900
Categories:
Characteristics-
PSA:
86.3
XLogP3:3
Appearance:Solid
Density:1'+-.0.06 g/cm3(Predicted)
Melting Point:208-209 °C @ Solvent: Dichloromethane, Hexane
Boiling Point:754.9ºC at 760 mmHg
Flash Point:410.3ºC
Water Solubility:Very soluble in water at pH < 5.5 (mesylate salt)
Storage Conditions:Refrigerator
Vapor Pressure:6.03E-24mmHg at 25°C
Collision Cross Section:214.6 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]
Hazard IdentificationClassification of the substance or mixture
Germ cell mutagenicity, Category 2
Carcinogenicity, Category 2
Reproductive toxicity, Category 1B
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Danger
Hazard statement(s) H341 Suspected of causing genetic defects
H351 Suspected of causing cancer
H360 May damage fertility or the unborn child
H362 May cause harm to breast-fed children
Precautionary statement(s) Prevention P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Imatinib mesylate
-
Location:
No.21,HuanCheng West Road ,AnQing City ,Anhui Province,China
-
Payment Terms:
D/P,L/C,D/A
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2009
Company Certificates-
business license
-
ISO9001
ANHUI HAIKANG PHARMACEUTICAL CO.,LTD. was established in 2009 in Anqing City, Anhui Province. It is located along the north bank of mid and lower reaches of the Yangtze River. Enjoying favorable geographic superiorities and convenient transportation infrastructure: such as highway, high speed railway, airport, inland shipping container terminal and so on. By plane, it takes just 1 hour to Shanghai, 2 hours to Guangzhou or Beijing; by high speed train it takes 2 hours to reach Nanjing, 4 hours to Shanghai, 6.5 hours Beijing.Since founded the company has been committed to the production, sales and export of chemical raw materials of pharmaceutical APIs and intermediates, while as well as other services of product customization, process improvement, achievement transfer,etc.
The company covers an area of 28000 square meters. We invested 80 million Yuan to set up 3 synthesis workshops and 3 purification workshops, whose annual output value is over hundred million Yuan, and their profits and taxes are over 20 million Yuan. All our productions are in strict accordance with GMP standard and we have established a well-equipped R & D center.
Haikang currently employs 50 people. 2 of them are of doctoral degree, 6 of master degree,1 researcher returned from overseas and all the rest employees have at least college education. We have close cooperation with Zhejiang University of Technology, University of Science and Technology of China and Anhui University of Chinese Medicine ,etc. We have an academic advisors team consisting of experts and professors who have well background of medical profession and ample experience in pharmacy developing and marketing. It is a united, hard-working, courageous, rigorous and innovative team of elites.
Through years of unremitting efforts Haikang has made remarkable achievements in the R&D and production of anti-virus, antidiabetic series APIs and intermediates. The main products are ganciclovir, valganciclovir hydrochloride, valaciclovir HCL, silodosin, repaglinide, sitagliptin, imatinib and their intermediates. We have established long and stable relationship with nearly 100 domestic and international pharmaceutical manufacturers and research institutes.
To deal with increasingly fierce competition and challenges of economic globalization, Haikang adheres to the business philosophy of “Customer is First, Technology is Leading, Quality is Everything, Honesty for Development” and insists on developing scientifically, globally and diversely. Relying on our existing advantages, we focus on the integration of various resources, and actively optimize the system of decision-making, management and service. We keep up with the pace of the newest R&D trend in and outside China; keep continuous innovation to develop high-tech, market prospective products to satisfy different needs from different customers. While pursuing economic benefits, Haikang has also committed to spare no efforts to advanced environmental management. It is always a mission and moreover a responsibility for Haikang to take care of people’s health and protect the environment.
We have confidence in our future and looking forward to having sincere, win-win and brilliant cooperation with you!
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted
India
Imatinib
100 G Oct 17, 2025
Pakistan
Imatinib
1 KG Jul 23, 2025
India
Imatinib Methane Sulphate
100 KG Jun 9, 2025 Post an enquiry for this product
More from this Seller
-
-
-
((S)-3-Methyl-1-[2-(1-piperidinyl)phenyl]butylamin
Pharmaceutical Grade / 99%
-
-
-
-
Sitagliptin phosphate 99%
Pharmaceutical Grade / 99%
$1/MT FOB
-
-
-
-
Tofacitinib citrate 99%
Pharmaceutical Grade / 99%
$1/MT FOB
-
-
-
-
Sugammadex sodium 99%
Pharmaceutical Grade / 99%
$1/MT FOB
-
-
-
-
Loxo-101 99%
Pharmaceutical Grade / 99%
-
-
-
-
Ectoine sodium salt monohydrate 99%
Cosmetics Grade / 99%
-